WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳NO PRODUCTS · NO PROTOCOLS · NO VENDORS✳WE SELL NOTHING✳EVERY CLAIM → A PRIMARY SOURCE✳UNKNOWN IS A REAL ANSWER✳
← All Claim Checks
Source record · FDA labeling · reviewed July 17, 2026

The approval is real. The general weight-loss claim is not.

Misleading
The circulating claim

“Tesamorelin is FDA-approved for belly fat and general weight loss.”

What the source record says

EGRIFTA products have a narrow FDA-approved use: reducing excess abdominal fat in adults with HIV and lipodystrophy. The label explicitly says the product is not indicated for weight-loss management.

Why the claim misleads

A real product approval is being widened from one defined HIV-associated condition to anyone seeking weight loss or body-composition change.

Correction

The approval is real. The general weight-loss claim is not.

Primary sources
FDA-approved EGRIFTA WR labelingOpen source ↗Tesamorelin library entryOpen source ↗
What changed

Added the source-verified Claim Check to the structured claim/source/change registry.

What would change our answer

A well-controlled human study tied to the exact product, population, route, and claimed outcome could change the answer. Mechanism, anecdotes, or a different product cannot substitute for that evidence.

Version history · 1 entry
  1. v1 · 2026-07-17Initial structured record created from the reviewed Claim Check.Source ↗
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.